Navigation Links
UT Southwestern scientist receives NIH Director's New Innovator Award
Date:10/1/2007

DALLAS Oct. 1, 2007 Dr. Tawanda Gumbo, an assistant professor of infectious diseases at UT Southwestern Medical Center, has been named one of the inaugural winners of the National Institutes of Health Directors New Innovator Award.

Dr. Gumbo is one of three Texas scientists and one of 29 nationwide to be named recipients of the award, which provides $1.5 million each over five years and is designed to recognize bold ideas from some of the nations most innovative new scientists. More than 2,100 applications were submitted.

The New Innovator Awards are given to early-career researchers who havent yet received a research project grant from the NIH. The awards are part of the NIH Roadmap for Medical Research, which promotes interdisciplinary and innovative research.

Dr. Gumbos research focuses on tuberculosis and extensively drug-resistant tuberculosis, a newly identified strain of TB that leaves patients virtually untreatable using existing anti-TB drugs. He has published numerous scientific papers on TB, AIDS and other infectious diseases.

About one-third of the worlds population is infected with mycobacterium tuberculosis, the bacterium that causes TB, and as many as 2 million people die of the disease each year. TB, which is the leading cause of death among people infected with HIV/AIDS, kills more people than any other disease caused by a single infectious agent, according to NIH data.

Dr. Beth Levine, professor of internal medicine and microbiology and chief of the division of infectious diseases at UT Southwestern, called the award a great honor for Dr. Gumbo.

The problem of drug resistance is emerging worldwide, Dr. Levine said. The idea that there might be a way to add a drug to prevent the resistance as well as to shorten and simplify therapy for all TB strains has major global health implications for treating this disease.

In his laboratory, Dr. Gumbo measures how antimicrobial drugs behave and how microbes react to those drug concentrations. The aim is to use such information from pharmacokinetics and pharmacodynamics to kill mycobacterium tuberculosis and keep more strains of TB from developing.

Dr. Gumbo said he was thrilled to receive the award.

It will allow me to actually do particular experiments that started with some techniques that I pioneered in the lab using the hollow fiber model of tuberculosis, the native of Zimbabwe said. The typical tuberculosis treatment takes many, many months; usually six months and nine months in some situations. Hopefully, well reduce it to weeks.

Over the five years of the award, Dr. Gumbo will develop a treatment regimen based on blocking the mechanisms that tuberculosis bacteria use to avoid being killed by antibiotics.

Dr. Gumbo, who joined the UT Southwestern faculty in 2006, graduated from the University of Zimbabwe Medical School in Harare, and completed his residency in internal medicine at Case Western Reserve University. He then completed a three-year fellowship to study infectious diseases at the Cleveland Clinic Foundation.

He spent a year doing research at the University of Zimbabwe before accepting a position in 2000 at Albany Medical College and the Ordway Research Institute in Albany, N.Y.

The other winners from Texas were Dr. Pedro Fernandez-Funez of the UT Medical Branch at Galveston and Dr. Kjersti Aagaard-Tillery of Baylor College of Medicine in Houston.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Scientists plan human cloning clinic in the United States
3. Scientists crack mechanism of Leptin-Obesity Hormone
4. Scientists use plant hormones to fight cancer
5. American scientists alter gene makeup of babies
6. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
7. Scientists found ancient Human Germ Killer
8. Scientists locate key hormone involved in appetite control
9. Scientists open the book of life
10. Electronic nose by Italian scientists
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Researchers at the University of ... well as a marker that may predict response to a particular class of drugs, ... of cancer as well. The new findings were published in Proceedings of the National ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Biscom Document Router (BDR), the first IoT device from Biscom designed to deliver ... Biscom will debut BDR at HIMSS17 and will be conducting demonstrations ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... ... 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related Disorders ... E. Cheese’s locations throughout New England, New York and New Jersey to provide children ... fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After a ...
(Date:2/19/2017)... ... , ... The Citadel’s new Swain Department of Nursing , along with ... Ph.D. Joseph was engaged by the college as a consultant to help build the ... a nation-wide search, she was selected to head the department as nurse administrator, assuming ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... India , February 20, 2017 According to ... (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), ... 2021" published by MarketsandMarkets, The market is projected to reach USD 52.37 ... of 6.5% during the forecast period. Continue ... ...
(Date:2/20/2017)... 2017   Alberty   Drugs , ... has announced a significant shift in focus ... programs to servicing local Veteran Affairs Centers (VA) and ... an increased need to secure cost effective treatments for ... locally for their goods & services. "The ...
(Date:2/20/2017)... Acute, Chronic and Prophylaxis GVHD The global graft versus ... from 2016-2021 and CAGR of 3% from 2021-2027. The market is expected ... market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn ... How this report ... the future business opportunities emerging in this sector. In this ...
Breaking Medicine Technology: